• Facebook
  • Twitter
  • Youtube
  • Instagram
  • LinkedIn
  • Rss
  • Store
  • Donate
NCCS - National Coalition for Cancer Survivorship
  • About
    • Our Mission
    • Our History
    • The 1986 Club
    • Our Team
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • State of Survivorship Survey
      • 2022 Survey
      • 2021 Survey
      • 2020 Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Advocate Engagement Opportunities
    • Survivorship Champions
    • Subscribe to NCCS Updates
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State-Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Cancer Rehabilitation
    • Integrative Oncology
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Telehealth
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • 2022 Winners
      • Awardees
      • Reception and Sponsorship
      • Committees
      • Nominations
    • Cancer Policy Roundtable (CPR)
      • Fall 2022 CPR
      • Spring 2022 CPR
      • Fall 2021 CPR
      • Spring 2021 CPR
      • Fall 2020 CPR
      • Spring 2020 CPR
    • Cancer Policy and Advocacy Team (CPAT) Virtual Symposium 2022
    • 2022 State of Survivorship Survey Results
    • Webinars
  • Contact Us
  • Search
  • Menu Menu
  • 0Shopping Cart

Your generous year-end donation will be matched $1 for $1    DONATE

Fotolia 23428619 S e1461260836640

NCCS Joins Cancer Leadership Council to Oppose the Latest Version of Right to Try Act

March 13, 2018/in Cancer News, Cancer Policy Blog, NCCS News, Policy Comments Access to Care, Clinical Trials NCCS News, Policy Comments
US CapitolNCCS joined the Cancer Leadership Council to express serious reservations about the latest version of the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act, released on March 10, 2018.

We oppose the latest version of right to try legislation because it makes a hollow promise to patients and removes the Food and Drug Administration (FDA) from approval and consultation in the expanded access process, a change that is not in the best interest of people with cancer.

Read the full letter below.


CANCER LEADERSHIP COUNCIL

A PATIENT-CENTERED FORUM OF NATIONAL ADVOCACY ORGANIZATIONS
ADDRESSING PUBLIC POLICY ISSUES IN CANCER

March 13, 2018

The Honorable Paul Ryan
Speaker
House of Representatives
H-232, The Capitol
Washington, DC 20515

The Honorable Nancy Pelosi
Minority Leader
House of Representatives
H-204, The Capitol
Washington, DC 20515

Dear Speaker Ryan and Leader Pelosi:

The undersigned cancer organizations, representing cancer patients, health care professionals, and researchers, are writing to express serious reservations about the latest version of the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act, released on March 10, 2018. We oppose the latest version of right to try legislation because it removes the Food and Drug Administration (FDA) from approval and consultation in the expanded access process, a change that is not in the best interest of people with cancer.

Our organizations have over many years sought to improve access to investigational agents while still protecting the research, development, and regulatory review of new agents. We have focused on improvements to the expanded access process, better communication about expanded access to physicians and patients, and more transparency from drug developers about their policies on expanded access. These enhancements in the process – and some efforts still underway or in implementation phase – have made a substantial difference in how patients obtain access to investigational agents.

As we have sought improvements in the process, we have maintained that FDA should remain a part of the expanded access process. The judgment of the agency about patient access to investigational agents is critical to protecting patients and ensuring them appropriate access to investigational agents.

In fact, FDA approves virtually all the expanded access requests that are presented to the agency. The agency is not the obstacle to patient access to investigational agents. If there are problems in submitting requests to the agency, those problems might be addressed through even more intensive education and outreach. Expanded access to investigational agents may be impeded by the decisions of drug developers attempting to complete their development programs. Right to try legislation will not address the decisions that drug developers make regarding expanded access.

We oppose the latest version of the right to try legislation because it makes a hollow promise to patients that, by removing FDA from the expanded access process, they will be assured access to investigational agents. And by removing FDA from the expanded access process, the legislation eliminates important protections for patients.

We urge that the House reject the right to try legislation.

Sincerely,

Cancer Leadership Council

American Society of Clinical Oncology
CancerCare
The Children’s Cause for Cancer Advocacy
Fight Colorectal Cancer
Hematology/Oncology Pharmacy Association
International Myeloma Foundation
The Leukemia & Lymphoma Society
Lymphoma Research Foundation
National Coalition for Cancer Survivorship
Prevent Cancer Foundation
Sarcoma Foundation of America
Susan G. Komen

# # #

Download the full letter » [PDF]


Related Post

https://canceradvocacy.org/policy-comments/nccs-letter-serious-reservations-right-to-try-legislation/


Read more NCCS Policy Comments »

Tags: drug approvals, policy comments, right to try
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
https://canceradvocacy.org/wp-content/uploads/2014/07/Fotolia_23428619_S-e1461260836640.jpg 515 1030 actualize https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png actualize2018-03-13 10:57:472018-03-13 10:57:47NCCS Joins Cancer Leadership Council to Oppose the Latest Version of Right to Try Act

Latest News

NCCS Letter to HHS

NCCS Urges CMS to Preserve Access to DIEP Flap Breast Reconstruction

June 1, 2023
Today, the Centers for Medicare and Medicaid Services (CMS) hosted a public meeting, in which they sought input on its decision to…
Read more
https://canceradvocacy.org/wp-content/uploads/HHS-Humphrey-bldg-1200-1030x515-1.jpg 515 1030 Kara Kenan https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png Kara Kenan2023-06-01 16:53:292023-06-01 16:53:29NCCS Urges CMS to Preserve Access to DIEP Flap Breast Reconstruction

Webinar – Survivorship at Atrium Health Wake Forest Baptist Comprehensive Cancer Center: Creating a Practical Workflow

May 12, 2023
The National Coalition for Cancer Survivorship (NCCS) hosted a Survivorship Champions webinar about survivorship care implementation,…
Read more
https://canceradvocacy.org/wp-content/uploads/Atrium-Health-Wake-Forest-Baptist-update-POST.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2023-05-12 12:42:192023-05-12 21:48:11Webinar – Survivorship at Atrium Health Wake Forest Baptist Comprehensive Cancer Center: Creating a Practical Workflow

Sandra Finestone, PsyD: Be Bold and Don’t Hesitate – A 30-year Survivor’s Advice on Advocacy

May 8, 2023
Advocate Spotlight: Sandra Finestone, PsyD A cancer diagnosis can be overwhelming and life-changing, but for Sandra Finestone, it…
Read more
https://canceradvocacy.org/wp-content/uploads/Sandra-Finestone-Advocate-Spotlight-Blog-Banner.png 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2023-05-08 13:42:472023-05-11 10:49:23Sandra Finestone, PsyD: Be Bold and Don’t Hesitate – A 30-year Survivor’s Advice on Advocacy

Take Action

Make An Impact

We are relentless in improving the quality of care and life after a cancer diagnosis. Your support makes all the difference right now.

Make a Gift »

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Share Your Story

NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

  • This field is for validation purposes and should be left unchanged.

  • About
    • Our Mission
    • Our History
    • The 1986 Club
    • Our Team
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • State of Survivorship Survey
      • 2022 Survey
      • 2021 Survey
      • 2020 Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Advocate Engagement Opportunities
    • Survivorship Champions
    • Subscribe to NCCS Updates
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State-Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Cancer Rehabilitation
    • Integrative Oncology
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Telehealth
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • 2022 Winners
      • Awardees
      • Reception and Sponsorship
      • Committees
      • Nominations
    • Cancer Policy Roundtable (CPR)
      • Fall 2022 CPR
      • Spring 2022 CPR
      • Fall 2021 CPR
      • Spring 2021 CPR
      • Fall 2020 CPR
      • Spring 2020 CPR
    • Cancer Policy and Advocacy Team (CPAT) Virtual Symposium 2022
    • 2022 State of Survivorship Survey Results
    • Webinars
  • Contact Us

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2023 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.

WCOE: HHS Hints at Lax ACA Regulation; Burden of High Drug Costs; FDA’s...NCCS Starburst 250pxNCCS Starburst 250pxWCOE: No Action on ACA Stabilization Bill; ‘Black Cancer Matters’;...
Scroll to top
Download the Survey Report

"*" indicates required fields

Fill out the form below, and we’ll send the survey report, detailed presentation, and infographic to your email.
Name*
I am a...*
Select any/all that apply.
Consent*
By downloading the survey materials, you will receive updates and information from NCCS via email, which you may unsubscribe from at any time. Your information will never be sold to any third parties.
This field is for validation purposes and should be left unchanged.

Get Updates From NCCS

Be the first to hear about cancer policy and survivorship issues! Subscribe and receive the biweekly NCCS Health Care Roundup, invites to webinars and events, and more.

  • This field is for validation purposes and should be left unchanged.

Connect With Us

Twitter     Facebook     Instagram     LinkedIn     YouTube

Harmar Brereton, MD

Founder
Northeast Regional Cancer Institute

 

“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”

—Karen M. Saunders
President, Northeast Regional Cancer Institute